» Articles » PMID: 24022019

Nasal Potential Difference Measurements in Diagnosis of Cystic Fibrosis: an International Survey

Overview
Journal J Cyst Fibros
Publisher Elsevier
Specialty Pulmonary Medicine
Date 2013 Sep 12
PMID 24022019
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The role of nasal potential difference (NPD) measurement as a diagnostic test for cystic fibrosis (CF) is a subject of global controversy because of the lack of validation studies, clear reference values, and standardized protocols for diagnostic NPD.

Methods: To determine diagnostic NPD frequency, protocols, interpretation, and rater agreement, we surveyed the 18 NPD centres of the European Cystic Fibrosis Society Diagnostic Network Working Group.

Results: Fifteen centres reported performing 373 diagnostic NPDs in 2012. Most use the CFF-TDN-SOP (67%) and the chloride-free + isoproterenol response of the side with the largest response (47%) as diagnostic criteria and use centre-specific reference ranges. Rater agreement for five NPD tracings - in general - was good, but poor in tracings with different responses between the two nostrils.

Conclusions: NPD is frequently used as a diagnostic and research tool for CF. Performance is highly standardized, centre-specific reference ranges are established, and rater agreement - in general - is good. Centre-independent diagnostic criteria and reference ranges must be defined by multicentre validation studies to improve standardized interpretation for diagnostic use.

Citing Articles

A systematic review of animal and human data comparing the nasal potential difference test between cystic fibrosis and control.

Leenaars C, Stafleu F, Hager C, Nieraad H, Bleich A Sci Rep. 2024; 14(1):9664.

PMID: 38671057 PMC: 11053161. DOI: 10.1038/s41598-024-60389-9.


A Systematic Review of the Effect of Cystic Fibrosis Treatments on the Nasal Potential Difference Test in Animals and Humans.

Leenaars C, Hager C, Stafleu F, Nieraad H, Bleich A Diagnostics (Basel). 2023; 13(19).

PMID: 37835841 PMC: 10572895. DOI: 10.3390/diagnostics13193098.


Personalized medicine with drugs targeting the underlying protein defect in cystic fibrosis: is monitoring of treatment response necessary?.

Niedermayr K, Gasser V, Rueckes-Nilges C, Appelt D, Eder J, Fuchs T Ther Adv Chronic Dis. 2022; 13:20406223221108627.

PMID: 35959505 PMC: 9358561. DOI: 10.1177/20406223221108627.


Ocular Surface Potential Difference Measured in Human Subjects to Study Ocular Surface Ion Transport.

Pasricha N, Smith A, Levin M, Schallhorn J, Verkman A Transl Vis Sci Technol. 2020; 9(11):20.

PMID: 33117611 PMC: 7571274. DOI: 10.1167/tvst.9.11.20.


Gene Therapy for Respiratory Diseases: Progress and a Changing Context.

Alton E, Boyd A, Davies J, Gill D, Griesenbach U, Harman T Hum Gene Ther. 2020; 31(17-18):911-916.

PMID: 32746737 PMC: 7499889. DOI: 10.1089/hum.2020.142.